Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
PHENDIMETRAZINE TARTRATE vs CETIRIZINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Phendimetrazine is a sympathomimetic amine that acts as an appetite suppressant by stimulating the hypothalamus to release norepinephrine, leading to decreased food intake and increased energy expenditure. It is a prodrug that is metabolized to phenmetrazine, which is a potent central nervous system stimulant with amphetamine-like effects.
Cetirizine is a second-generation antihistamine that selectively inhibits peripheral H1 receptors, reducing histamine-mediated allergic responses. Pseudoephedrine is a sympathomimetic amine that acts as an alpha-adrenergic agonist, causing vasoconstriction and decongestion of nasal mucosa.
Management of exogenous obesity as a short-term adjunct (a few weeks) in a regimen of weight reduction based on caloric restriction,Off-label: treatment of obesity with comorbid conditions where weight loss is beneficial
Relief of symptoms of seasonal allergic rhinitis such as sneezing, rhinorrhea, and nasal congestion,Relief of nasal congestion due to common cold or upper respiratory allergies
Oral: 35 mg twice daily or three times daily, 1 hour before meals; extended-release: 105 mg once daily in the morning.
1 tablet (5 mg cetirizine / 120 mg pseudoephedrine) orally every 12 hours; maximum 2 tablets per day.
Terminal half-life 3-4 hours; clinical context: requires multiple daily dosing
Cetirizine: terminal half-life ~8.3 hours in healthy adults (prolonged to 20-30 hours in renal impairment). Pseudoephedrine: terminal half-life ~4-8 hours (p H-dependent urinary excretion; prolonged in alkaline urine).
Primarily metabolized in the liver via N-demethylation to its active metabolite, phenmetrazine. Other metabolites include phendimetrazine N-oxide and norphenmetrazine. CYP450 enzymes are involved, though specific isoforms not well characterized.
Cetirizine undergoes minimal hepatic metabolism via oxidation to an inactive metabolite, primarily excreted unchanged in urine. Pseudoephedrine is partially metabolized in the liver by N-demethylation to an active metabolite, with about 50-75% excreted unchanged in urine.
Primarily renal (≥70% unchanged) with minor biliary/fecal elimination (<10%)
Cetirizine: approximately 70% excreted unchanged in urine via glomerular filtration and tubular secretion; about 10% in feces. Pseudoephedrine: 70-90% excreted unchanged in urine; remainder as inactive metabolites.
10-15% bound to albumin
Cetirizine: 93% bound to albumin. Pseudoephedrine: not significantly protein bound (<10%).
2-3 L/kg; indicates extensive tissue distribution
Cetirizine: 0.5-0.8 L/kg (total body water). Pseudoephedrine: 2.6-3.5 L/kg (extensive tissue distribution).
Oral: approximately 80-90%
Cetirizine: oral bioavailability ~70% (not affected by food). Pseudoephedrine: oral bioavailability ~100% (first-pass metabolism minimal).
Contraindicated in severe renal impairment (GFR < 30 m L/min). No specific dose adjustments for mild-moderate impairment; use with caution.
GFR 30-49 m L/min: 1 tablet every 24 hours. GFR <30 m L/min or dialysis: contraindicated.
Not recommended in Child-Pugh class B or C. Use with caution in mild impairment.
Child-Pugh A or B: no dose adjustment required. Child-Pugh C: contraindicated due to lack of data.
Not recommended for children under 12 years; safety and efficacy not established.
Children <12 years: not approved. Children ≥12 years: same as adult dosing (5 mg/120 mg every 12 hours).
Start at lower end of dosing range; monitor for increased sensitivity and cardiovascular effects.
Use with caution; start with 1 tablet every 24 hours due to increased sensitivity and risk of anticholinergic effects.
Phendimetrazine is not approved for use in patients with a history of drug abuse or dependence. It has a high potential for abuse and may lead to dependence. Use caution in patients with cardiovascular disease or hypertension.
None
Increased risk of pulmonary hypertension and valvular heart disease; monitor for dyspnea, chest pain, or edema. Tolerance may develop; discontinue if tolerance occurs. May impair ability to perform hazardous tasks. Use with caution in patients with hypertension, diabetes, or glaucoma. Do not use with MAOIs or within 14 days of discontinuation.
Cardiovascular effects: Use with caution in patients with hypertension, cardiovascular disease, or ischemic heart disease due to pseudoephedrine's vasoconstrictive and positive chronotropic effects,Cerebrovascular effects: Pseudoephedrine may cause ischemic colitis, hemorrhagic stroke, or vasospasm; avoid in patients with history of stroke or vasculopathy,Nervous system effects: May cause insomnia, nervousness, or seizure; use with caution in elderly or those with seizure disorders,Renal impairment: Dose adjustment for cetirizine necessary in moderate to severe renal impairment,Drug interactions: Avoid MAO inhibitors or use within 14 days; concomitant use with other sympathomimetics may increase adverse effects
Hypersensitivity to phendimetrazine or any component of the formulation, advanced arteriosclerosis, symptomatic cardiovascular disease, moderate to severe hypertension, hyperthyroidism, glaucoma, agitated states, history of drug abuse, during or within 14 days of MAOI therapy
Hypersensitivity to cetirizine, pseudoephedrine, or any components,Severe hypertension or coronary artery disease,Use of monoamine oxidase inhibitors (MAOIs) currently or within 14 days,Narrow-angle glaucoma,Urinary retention,Severe renal impairment (Cr Cl <10 m L/min) for cetirizine component
Avoid alcohol and excessive caffeine (coffee, tea, energy drinks) as they may increase CNS stimulation and risk of side effects. Take with or without food; high-fat meals may delay absorption of extended-release formulations. Maintain a calorie-reduced diet as part of a comprehensive weight loss plan.
No significant food interactions. Avoid concurrent use of caffeine or other stimulants (e.g., coffee, tea, energy drinks) as pseudoephedrine may additive CNS stimulation. Take without regard to meals; fatty meals may delay absorption of cetirizine but not clinically relevant.
First trimester: Limited data; potential for increased risk of oral clefts. Second/third trimester: Anorexiant effects may cause fetal growth restriction; avoid use due to maternal hypertension risk.
Category B: No evidence of risk in humans. Cetirizine: no increased malformations in epidemiologic studies. Pseudoephedrine: potential risk of gastroschisis in first trimester; avoid first trimester. Second/third trimester: no known fetal risks; monitor for reduced uterine blood flow due to vasoconstriction.
Excreted in breast milk; M/P ratio unknown. Contraindicated in breastfeeding due to potential CNS stimulation and cardiovascular effects in infant.
Small amounts excreted in breast milk. M/P ratio not established for combination. Cetirizine M/P ~0.25-1.3. Pseudoephedrine M/P ~2.6-3.5; may reduce milk production. Use with caution, especially in preterm infants. Monitor infant for irritability, sleep disturbance.
Contraindicated in pregnancy; no dose adjustments recommended. Avoid use due to risks of hypertension and potential teratogenicity.
No pharmacokinetic changes requiring routine dose adjustment in pregnancy. However, increased renal clearance may reduce cetirizine levels; clinical significance unclear. Avoid excessive pseudoephedrine due to vasoconstriction; use lowest effective dose.
Phendimetrazine tartrate is a schedule III controlled substance with high abuse potential. It is approved only for short-term (up to 12 weeks) monotherapy for exogenous obesity. Contraindicated in patients with glaucoma, hyperthyroidism, agitated states, history of drug abuse, or cardiovascular disease. Taper dose to avoid withdrawal. Monitor blood pressure and heart rate; may cause pulmonary hypertension. Avoid use with MAOIs (risk of hypertensive crisis) and within 14 days of discontinuation.
Cetirizine/pseudoephedrine combines a second-generation antihistamine with a sympathomimetic decongestant. Avoid in patients with severe hypertension, coronary artery disease, or narrow-angle glaucoma. Use caution in hyperthyroidism, diabetes, and prostate hyperplasia. Monitor for CNS stimulation (insomnia, nervousness) especially in evening dosing. Cetirizine is less sedating than first-generation antihistamines but may still cause drowsiness; pseudoephedrine can counteract sedation. Contraindicated with MAOIs or within 14 days of use. Not recommended in pregnancy category B (cetirizine) but pseudoephedrine crosses placenta; avoid in lactation.
Take exactly as prescribed; do not increase dose or duration.,Take last dose of the day 4-6 hours before bedtime to prevent insomnia.,Do not crush or chew extended-release tablets; swallow whole.,Avoid driving or operating heavy machinery until you know how this medication affects you.,Report chest pain, shortness of breath, fainting, or leg swelling immediately.,Do not stop abruptly; follow your doctor's tapering plan.,Store securely; keep out of reach of others as this medication can be habit-forming.,Do not take with alcohol or other CNS stimulants.,Use with caution if you have high blood pressure, diabetes, or a history of depression.
Take this medication by mouth with or without food, with a full glass of water.,Do not crush or chew extended-release tablets; swallow whole.,Avoid alcohol, as it can increase drowsiness and side effects.,May cause drowsiness or dizziness; use caution when driving or operating machinery.,Do not exceed recommended dose; do not take more than every 12 hours.,Report rapid or irregular heartbeat, chest pain, or severe dizziness.,Discontinue use and consult doctor if symptoms persist after 7 days or with fever.,Avoid taking with other cold, allergy, or sleep aids without approval.,If you have high blood pressure, heart disease, or urinary retention, consult doctor before use.,Store at room temperature, away from moisture and heat.
"Normethadone, an opioid analgesic with QT-prolonging properties, combined with cetirizine, a second-generation antihistamine that can also prolong the QT interval, increases the risk of additive cardiotoxicity, specifically potentially fatal ventricular arrhythmias like torsade de pointes. This interaction is most concerning in patients with preexisting QT prolongation, electrolyte disturbances, or those taking other QT-prolonging agents. Clinical outcomes may include palpitations, syncope, or sudden cardiac death."
"Cetirizine is a second-generation antihistamine that selectively blocks peripheral H1 receptors, while cyproheptadine is a first-generation antihistamine with additional antiserotonergic and anticholinergic properties. When coadministered, additive central nervous system depression may occur, leading to excessive sedation, dizziness, and psychomotor impairment. Concurrent use also potentiates anticholinergic adverse effects such as dry mouth, urinary retention, and blurred vision, particularly in elderly patients."
"Concurrent use of flupentixol and cetirizine may result in additive central nervous system depression, including increased sedation, drowsiness, and psychomotor impairment. Flupentixol, a thioxanthene antipsychotic with prominent antihistaminergic (H1) and antidopaminergic effects, combined with cetirizine, a peripheral H1-antihistamine with limited central penetration but dose-related sedative potential, can lead to exaggerated CNS and respiratory depression, altered cognitive function, and reduced reaction time. These effects increase the risk of falls, accidents, and respiratory compromise, particularly in elderly or debilitated patients."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about PHENDIMETRAZINE TARTRATE vs CETIRIZINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE, answered by our medical review team.
PHENDIMETRAZINE TARTRATE is a Anorectic (Sympathomimetic) that works by Phendimetrazine is a sympathomimetic amine that acts as an appetite suppressant by stimulating the hypothalamus to release norepinephrine, leading to decreased food intake and increased energy expenditure. It is a prodrug that is metabolized to phenmetrazine, which is a potent central nervous system stimulant with amphetamine-like effects.. CETIRIZINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE is a Sympathomimetic that works by Cetirizine is a second-generation antihistamine that selectively inhibits peripheral H1 receptors, reducing histamine-mediated allergic responses. Pseudoephedrine is a sympathomimetic amine that acts as an alpha-adrenergic agonist, causing vasoconstriction and decongestion of nasal mucosa.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between PHENDIMETRAZINE TARTRATE and CETIRIZINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of PHENDIMETRAZINE TARTRATE is: Oral: 35 mg twice daily or three times daily, 1 hour before meals; extended-release: 105 mg once daily in the morning.. The standard adult dose of CETIRIZINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE is: 1 tablet (5 mg cetirizine / 120 mg pseudoephedrine) orally every 12 hours; maximum 2 tablets per day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between PHENDIMETRAZINE TARTRATE and CETIRIZINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. PHENDIMETRAZINE TARTRATE is classified as Category C. First trimester: Limited data; potential for increased risk of oral clefts. Second/third trimester: Anorexiant effects may cause fetal growth restriction; avoid use due to maternal. CETIRIZINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE is classified as Category A/B. Category B: No evidence of risk in humans. Cetirizine: no increased malformations in epidemiologic studies. Pseudoephedrine: potential risk of gastroschisis in first trimester; avo. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.